Pricing Log in Create free account
Friday 6 November 2026 Export CAI’s income statement to Excel — free account

Caris Life Sciences,�Inc.

CAI Healthcare Biotechnology

Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.

Revenue
+27.0%
EPS
−40.3%
Free cash flow
−140.2%
Total debt
+4.46%

Quarter to September 2026, against a year earlier

25.52 0.51 −1.96%
Market cap
$7.4B
P/E
77.7×
Fwd P/E
254×
Dividend yield
—
F-score
n/a
Altman Z
3.55
Beneish M
−2.71
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Caris Life Sciences,�Inc. (CAI) Revenue

Alert me on Revenue

Caris Life Sciences,�Inc.'s revenue for fiscal 2025 was $812.0M, up 97.0% from $412.3M in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.0B. Caris Life Sciences,�Inc. ranks 24th of 390 Biotechnology companies by revenue.

Revenue, annual

Embed this chart

Annual newest first

Period Revenue Change
FY2025 $812.0M 96.97%
FY2024 $412.3M 34.67%
FY2023 $306.1M —

Quarterly newest first

Period Revenue Change
Sep 2026 $275.4M 4.42%
Jun 2026 $263.7M 21.99%
Mar 2026 $216.2M (26.19%)
Dec 2025 $292.9M 35.07%
5 more quarters

Revenue against peers

Company Revenue
MDGL Madrigal Pharmaceuticals, Inc. compare $1.4B
CAI Caris Life Sciences,�Inc. $1.0B
TGTX TG Therapeutics, Inc. compare $799.5M
KRYS Krystal Biotech, Inc. compare $470.0M
TWST Twist Bioscience Corporation compare $431.8M
PTGX Protagonist Therapeutics, Inc. compare $282.0M
IBRX ImmunityBio, Inc. compare $165.8M
CYTK Cytokinetics, Incorporated compare $113.3M
SYRE Spyre Therapeutics, Inc. compare $1.1M

What Revenue is

Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.

Reported line item

The full definition of Revenue →

More on CAI